BE2021C557I2 - - Google Patents

Info

Publication number: BE2021C557I2
Authority: BE; Belgium

Application number

BE2021C557C

Other languages

Original Assignee

Ipsen Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-08

Filing date

2021-12-07

Publication date

2026-01-14

2021-12-07 Application filed by Ipsen Pharma filed Critical Ipsen Pharma

2026-01-14 Publication of BE2021C557I2 publication Critical patent/BE2021C557I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Toxicology (AREA)
Zoology (AREA)

BE2021C557C 2005-07-08 2021-12-07 BE2021C557I2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69777905P	2005-07-08	2005-07-08
US74885005P	2005-12-09	2005-12-09

Publications (1)

Publication Number	Publication Date
BE2021C557I2 true BE2021C557I2 (ru)	2026-01-14

Family

ID=37637790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2021C557C BE2021C557I2 (ru)	2005-07-08	2021-12-07

Country Status (21)

Country	Link
US (8)	US8039435B2 (ru)
EP (6)	EP2236151B1 (ru)
JP (4)	JP4734411B2 (ru)
KR (2)	KR100997177B1 (ru)
CN (5)	CN101676298A (ru)
AU (2)	AU2006269261B2 (ru)
BE (1)	BE2021C557I2 (ru)
CA (4)	CA2614615C (ru)
DK (4)	DK3354273T3 (ru)
ES (4)	ES2386862T3 (ru)
FR (1)	FR21C1060I2 (ru)
HU (4)	HUE031731T2 (ru)
IL (3)	IL188545A (ru)
NL (1)	NL301150I2 (ru)
NZ (2)	NZ580806A (ru)
PL (4)	PL2286825T3 (ru)
PT (4)	PT2286825T (ru)
RU (2)	RU2439079C2 (ru)
SG (1)	SG163585A1 (ru)
SI (1)	SI3354273T1 (ru)
WO (1)	WO2007008704A2 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE031731T2 (en) *	2005-07-08	2017-07-28	Ipsen Pharma	Melanocortin receptor ligands
DE102007020152A1 (de) *	2007-04-26	2008-10-30	Charité - Universitätsmedizin Berlin	Mittel zur antiinfektiven Behandlung eines Patienten
JP5250026B2 (ja)	2007-05-25	2013-07-31	イプセンファルマソシエテパールアクシオンサンプリフィエ	ヒダントインで修飾したメラノコルチン受容体リガンド
EP2167112A4 (en) *	2007-06-15	2012-01-25	Ipsen Pharma Sas	CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
CA2704651C (en)	2007-11-05	2017-03-07	Ipsen Pharma S.A.S.	Use of melanocortins to treat insulin sensitivity
CN102143970B (zh)	2008-05-27	2017-02-08	健赞股份有限公司	α‑促黑素细胞激素的肽类似物
AU2009257631B2 (en)	2008-06-09	2014-07-24	Palatin Technologies, Inc.	Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (es)	2009-06-08	2011-01-31	Astrazeneca Ab	Péptidos específicos para receptores de melanocortina
EP2440572B1 (en)	2009-06-08	2017-04-05	Palatin Technologies, Inc.	Lactam-bridged melanocortin receptor-specific peptides
AU2010259008C1 (en)	2009-06-08	2016-04-21	Palatin Technologies, Inc.	Melanocortin receptor-specific peptides
JP2013501053A (ja) *	2009-08-05	2013-01-10	イプセンファルマソシエテパールアクシオンサンプリフィエ	脂質異常症を治療するためのメラノコルチンの使用
DK2473518T3 (en) *	2009-08-31	2017-03-27	Tensive Controls Inc	Stabilized melanocortin ligands
JP5486690B2 (ja) *	2009-11-16	2014-05-07	イプセンファルマソシエテパールアクシオンサンプリフィエ	メラノコルチン受容体リガンドの医薬組成物
RU2012125033A (ru) *	2009-11-16	2014-01-20	Ипсен Фарма С.А.С.	СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2781402C (en)	2009-11-23	2017-03-21	Palatin Technologies, Inc.	Melanocortin-1 receptor-specific cyclic peptides
CA2781405A1 (en)	2009-11-23	2011-05-26	Palatin Technologies, Inc.	Melanocortin-1 receptor-specific linear peptides
US9415012B2 (en)	2011-06-14	2016-08-16	Ipsen Pharma S.A.S.	Sustained-release composition containing peptides as active ingredient
LT3539551T (lt)	2011-12-29	2022-01-10	Rhythm Pharmaceuticals, Inc.	Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
EP2705835A1 (en)	2012-06-08	2014-03-12	Ipsen Pharma S.A.S.	Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
ES2538702T3 (es)	2012-10-19	2015-06-23	Txp Pharma Gmbh	Análogos de MSH-alfa y MSH-gamma
US10232018B2 (en)	2013-03-14	2019-03-19	Mallinckrodt Ard Ip Limited	ACTH for treatment of acute respiratory distress syndrome
EP3450449A3 (en) *	2013-03-15	2019-06-12	Rhythm Pharmaceuticals, Inc.	Peptide compositions
EP2970389B1 (en)	2013-03-15	2020-08-19	Rhythm Pharmaceuticals, Inc.	Pharmaceutical compositions
ES2854353T3 (es)	2014-04-22	2021-09-21	Txp Pharma Gmbh	Análogos péptidicos con sonda(s) aminoacídicas ramificadas
CN108601816A (zh) *	2015-09-30	2018-09-28	节奏制药公司	治疗黑皮质素-4受体路径相关联病症的方法
US10653743B2 (en) *	2015-10-15	2020-05-19	Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US11542302B2 (en)	2015-10-15	2023-01-03	Arizona Board Of Regents On Behalf Of The University Of Arizona	Modulators of melanocortin receptors for the treatment of depression and anxiety
US20190255142A1 (en) *	2016-10-17	2019-08-22	Arizona Board Of Regents On Behalf Of The University Of Arizona	Novel modulators of melanocortin receptors for the treatment of depression and anxiety
MA49883A (fr) *	2017-03-15	2021-04-21	Novo Nordisk As	Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
CA3096055A1 (en)	2018-04-06	2019-10-10	Rhythm Pharmaceuticals, Inc.	Compositions for treating kidney disease
WO2019219714A1 (en) *	2018-05-15	2019-11-21	Novo Nordisk A/S	Compounds capable of binding to melanocortin 4 receptor
AU2019273132B2 (en) *	2018-05-23	2024-10-03	Provincial Health Services Authority	Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en)	2019-03-01	2022-07-26	Provincial Health Services Authority	Cyclic peptide analogs of melanocortin and amanitin and methods of making such
AR123603A1 (es) *	2020-09-24	2022-12-21	Rhythm Pharmaceuticals Inc	Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina
WO2022204305A2 (en) *	2021-03-24	2022-09-29	Glo Pharma, Inc.	Peptides and methods for reducing skin pigmentation
JP2024522348A (ja) *	2021-05-27	2024-06-18	ザリージェンツオブザユニバーシティオブミシガン	Ｍｃ３ｒアゴニストペプチド
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025123055A1 (en) *	2023-12-07	2025-06-12	Endevica Bio, Inc.	Non-naturally occurring melanocortin analogs and associated methods for modulating weight gain

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US613874A (en)		1898-11-08		George e
US1613874A (en)	1922-03-29	1927-01-11	Miner Inc W H	Friction draft gear
US5652214A (en)	1989-06-05	1997-07-29	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5665702A (en)	1995-06-06	1997-09-09	Biomeasure Incorporated	Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en)	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
SE9700620D0 (sv)	1997-02-21	1997-02-21	Wapharm Ab	Cykliska peptider med selektivitet för MSH-receptor subtyper
WO1999021571A1 (en)	1997-10-27	1999-05-06	Trega Biosciences, Inc.	Melanocortin receptor ligands and methods of using same
WO1999055679A1 (en) *	1998-04-28	1999-11-04	Trega Biosciences, Inc.	Isoquinoline compound melanocortin receptor ligands and methods of using same
MXPA01001100A (es) *	1998-07-27	2002-08-20	Univ Iowa State Res Found Inc	Gen del receptor melanocortina-4 y su uso como un marcador genetico para contenido de grasa, ganacia de peso y7o consumo de alimento para animales.
WO2000010507A2 (en)	1998-08-21	2000-03-02	The Children's Medical Center Corporation	Use of melanin for inhibition of angiogenesis and macular degeneration
US6716810B1 (en)	1998-12-09	2004-04-06	Eleanor Roosevelt Institute	Composition and method for regulation of body weight and associated conditions
US6603058B1 (en)	1998-12-09	2003-08-05	Oklahoma Medical Research Foundation	Non-human animal model for obesity and uses thereof
IL145406A0 (en)	1999-03-29	2002-06-30	Procter & Gamble	Melanocortin receptor ligands
US7176279B2 (en) *	2000-06-28	2007-02-13	Palatin Technologies, Inc.	Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) *	1999-06-29	2003-06-17	Palatin Technologies, Inc.	Compositions and methods for treatment of sexual dysfunction
JP2003513645A (ja)	1999-11-12	2003-04-15	メルクエンドカムパニーインコーポレーテッド	メラノコルチン−３レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
US6600015B2 (en)	2000-04-04	2003-07-29	Hoffmann-La Roche Inc.	Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AP2001002196A0 (en) *	2000-06-28	2002-12-21	Pfizer Prod Inc	Melanocortin receptor ligands.
US6720324B2 (en)	2000-07-05	2004-04-13	Synaptic Pharmaceutical Corporation	Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MXPA03002160A (es)	2000-09-13	2004-05-04	Eleanor Roosevelt Inst	Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
US20030113263A1 (en)	2001-02-13	2003-06-19	Oregon Health And Sciences University, A Non-Profit Organization	Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
WO2002079146A2 (en)	2001-03-02	2002-10-10	Bristol-Myers Squibb Company	Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6770645B2 (en) *	2001-03-16	2004-08-03	Pfizer Inc.	Pharmaceutically active compounds
AU2002322466B2 (en) *	2001-07-11	2007-08-30	Palatin Technologies, Inc.	Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) *	2002-05-07	2006-04-25	University Of Florida	Peptides and methods for the control of obesity
US20040128136A1 (en) *	2002-09-20	2004-07-01	Irani Pourang Polad	Internet voice browser
JP2006527773A (ja) *	2003-06-19	2006-12-07	イーライリリーアンドカンパニー	メラノコルチン受容体４（ｍｃ４）作用薬とその用途
EP1644022A1 (en) *	2003-06-19	2006-04-12	Eli Lilly And Company	Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en)	2003-06-23	2006-08-01	University Of Florida Research Foundation, Inc.	Melanocortin receptor templates, peptides, and use thereof
WO2005019184A1 (en)	2003-08-20	2005-03-03	Eli Lilly And Company	Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
MXPA06001916A (es) *	2003-08-20	2006-05-17	Lilly Co Eli	Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
WO2005040109A1 (en) *	2003-10-22	2005-05-06	Neurocrine Biosciences, Inc.	Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de)	2003-11-21	2005-06-23	Orthogen Ag	Transskin
WO2005060985A1 (en)	2003-12-10	2005-07-07	Merck & Co., Inc.	Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
CA2557739A1 (en)	2004-03-29	2005-11-03	Eli Lilly And Company	Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
NZ554427A (en)	2004-10-08	2010-09-30	Clinuvel Pharmaceuticals Ltd	Compositions and methods for inducing melanogenesis in a subject utilising afamelanotide
WO2006073772A1 (en)	2005-01-05	2006-07-13	Eli Lilly And Company	Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en)	2005-01-05	2006-07-13	Eli Lilly And Company	Polyethylene glycol linked mc4r or mc3r agonist peptides
HUE031731T2 (en) *	2005-07-08	2017-07-28	Ipsen Pharma	Melanocortin receptor ligands
SI1919947T1 (sl)	2005-08-26	2013-06-28	Abbvie Inc.	Terapevtsko aktivni alfa-msh analogi

2006
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko active Active
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es active Active
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 CN CN202411273113.9A patent/CN119119190A/zh active Pending
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja active Active
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko active Active
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en not_active Ceased
- 2006-07-10 CN CN201610168908.2A patent/CN105837661B/zh active Active
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es active Active
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh active Active
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh active Active
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es active Active
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es active Active
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja active Active
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja active Active
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
2019
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-07 BE BE2021C557C patent/BE2021C557I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3925614A3 (en)	2022-03-23
CN105837661B (zh)	2024-10-15
JP2009500427A (ja)	2009-01-08
ES2604328T3 (es)	2017-03-06
US20220127305A1 (en)	2022-04-28
EP1915167A2 (en)	2008-04-30
KR20080049711A (ko)	2008-06-04
DK2548568T3 (en)	2018-03-12
ES2663916T3 (es)	2018-04-17
EP1915167A4 (en)	2010-04-07
EP2236151B1 (en)	2012-05-23
US20100279922A1 (en)	2010-11-04
KR20100016120A (ko)	2010-02-12
HUS2100054I1 (hu)	2021-12-28
PL2548568T3 (pl)	2018-06-29
AU2009230799A1 (en)	2009-11-19
HK1258965A1 (en)	2019-11-22
JP2015232003A (ja)	2015-12-24
PL2236151T3 (pl)	2012-10-31
KR101232201B1 (ko)	2013-02-12
ES2386862T3 (es)	2012-09-03
IL201732A (en)	2016-07-31
US20110183886A1 (en)	2011-07-28
FR21C1060I1 (fr)	2022-01-21
CN103755786B (zh)	2016-05-11
CN101257916B (zh)	2013-04-03
US20180105557A1 (en)	2018-04-19
CA2614615C (en)	2012-10-16
CA2793119A1 (en)	2007-01-18
US8039435B2 (en)	2011-10-18
FR21C1060I2 (fr)	2022-12-02
RU2008104803A (ru)	2009-08-20
AU2006269261B2 (en)	2009-12-17
NL301150I2 (nl)	2022-11-24
US9850280B2 (en)	2017-12-26
EP2286825A3 (en)	2011-07-27
WO2007008704A3 (en)	2007-10-11
AU2009230799B2 (en)	2012-02-09
PL2286825T3 (pl)	2017-06-30
EP3354273A1 (en)	2018-08-01
CN103755786A (zh)	2014-04-30
RU2009131092A (ru)	2011-02-20
HUE037147T2 (hu)	2018-08-28
IL188545A0 (en)	2008-04-13
US20170240595A1 (en)	2017-08-24
EP2236151A1 (en)	2010-10-06
SG163585A1 (en)	2010-08-30
CN101257916A (zh)	2008-09-03
RU2439079C2 (ru)	2012-01-10
HUE031731T2 (en)	2017-07-28
JP4734411B2 (ja)	2011-07-27
AU2006269261A1 (en)	2007-01-18
EP3925614A2 (en)	2021-12-22
US20160368962A1 (en)	2016-12-22
PL3354273T3 (pl)	2021-10-11
US9458195B2 (en)	2016-10-04
NL301150I1 (ru)	2021-12-08
WO2007008704A2 (en)	2007-01-18
RU2380372C2 (ru)	2010-01-27
PT2548568T (pt)	2018-03-21
KR100997177B1 (ko)	2010-11-29
DK3354273T3 (da)	2021-06-28
NZ565217A (en)	2010-03-26
JP5889513B2 (ja)	2016-03-22
HK1149190A1 (en)	2011-09-30
CN105837661A (zh)	2016-08-10
JP2010090130A (ja)	2010-04-22
JP5965520B2 (ja)	2016-08-03
EP3354273B1 (en)	2021-03-24
SI3354273T1 (sl)	2021-10-29
IL201732A0 (en)	2010-06-16
EP2548568A3 (en)	2013-07-17
DK2286825T3 (en)	2017-01-09
CN119119190A (zh)	2024-12-13
PT3354273T (pt)	2021-06-28
JP2013253090A (ja)	2013-12-19
PT2236151E (pt)	2012-07-02
NZ580806A (en)	2012-07-27
CN101676298A (zh)	2010-03-24
DK2236151T3 (da)	2012-07-09
IL246392A (en)	2017-07-31
US20200095281A1 (en)	2020-03-26
HUE055154T2 (hu)	2021-11-29
IL188545A (en)	2011-08-31
CA3228910A1 (en)	2007-01-18
PT2286825T (pt)	2017-01-02
EP2548568A2 (en)	2013-01-23
ES2877349T3 (es)	2021-11-16
CA2793119C (en)	2019-07-23
CA2614615A1 (en)	2007-01-18
EP2286825A2 (en)	2011-02-23
US20180305406A1 (en)	2018-10-25
EP2548568B1 (en)	2018-01-10
EP2286825B1 (en)	2016-09-28
CA3044795A1 (en)	2007-01-18

Publication	Publication Date	Title
BE2021C557I2 (ru)	2026-01-14
BE2018C028I2 (ru)	2025-09-05
BE2015C074I2 (ru)	2025-12-10
BE2014C012I2 (ru)	2026-01-14
BE2014C057I2 (ru)	2025-12-10
BE2013C074I2 (ru)	2025-09-17
BE2013C014I2 (ru)	2025-12-10
BE2012C042I2 (ru)	2021-07-19
BE2012C028I2 (ru)	2026-01-14
BRPI0601358B8 (pt)	2023-02-23	Aplicador de clipe cirúrgico
BRPI0601402B8 (pt)	2023-02-23	Aplicador de grampos cirúrgicos
BR122017004707A2 (ru)	2010-11-30
BRPI0609157A8 (ru)	2006-09-08
BRPI0608519A2 (ru)	2017-08-15
AP2140A (ru)	2010-08-06
JP2006027604A5 (ru)	2006-06-29
BRPI0604219A (ru)	2007-07-03
JP2006259330A5 (ru)	2008-04-24
JP2006247038A5 (ru)	2010-03-25
BRPI0618215B8 (ru)	2021-05-25
BY2237U (ru)	2005-12-30
JP2005236268A5 (ru)	2007-11-22
BE2017C062I2 (ru)	2025-12-03
CN105122969C (ru)	2010-03-10
CN300725995S (zh)	2008-01-02	鞋帮